HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Focus of geriatric oncology shifting from age to patient
• AIDS populations may receive cancer diagnosis at similar age as the general population
• Dual flu and pneumococcal vaccination may protect seniors from cardiovascular events
• Eight HPV types responsible for most cervical cancers worldwide
• High economic burden, rates of revascularization for patients with PAD
• High pHER-2 levels associated with inferior DFS in HER-2–positive breast cancer
• Hormone therapy likely to increase deaths from breast cancer
• Rasburicase more effective than allopurinol in controlling plasma uric acid in adults at high risk for tumor lysis
• Time to relapse after ibritumomab-tiuxetan treatment lower than that of previous treatments in follicular lymphoma
• Vitamin D insufficiency linked to inferior survival in patients with NHL
• Thyroid carcinoma metastatic to the skeleton with intense associated hypermetabolic activity Munir Ghesani, MD, FACNM; Neil Gupta, MD; Daniel Kuriloff, MD, FACS; Sumit Talwar, MD
• Black women less likely to receive locoregional, hormone therapy for breast cancer
• Sequential cisplatin-topotecan and carboplatin-paclitaxel increased toxicity with no improvement in efficacy in ovarian cancer
• Women with triple-negative breast cancer aged younger than 50 years may benefit from BRCA testing
• Abiraterone acetate increased survival in metastatic castration-resistant prostate cancer
• Everolimus increased PFS in rare neuroendocrine tumors
• Molecular test predicts survival in prostate cancer
• Nursing encouraged after pregnancy in breast cancer survivors
• Panitumumab did not significantly increase OS in recurrent, metastatic head/neck cancer
• Mind the fire: Managing and preventing burnout Stephanie M. Harman, MD, FACP